Skip to content

Contact +44 (0) 20 7060 7474 email us

Animal / Veterinary

Animal Pharm's Top Tier Companies

2007 edition

Publication Date January 2007
Publisher Animal Pharm
Product Type Report
Pages 271
ISBN Number not applicable
Product Code ANP00025

Price

£895.00
approximately: $1,355 | €999

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

For over a decade now, Animal Pharm has published an annual 'Top 20 Companies' report containing detailed profiles of leading businesses in the global animal health and nutrition products sector. During that time, the structure of the industry has altered significantly. Merger and acquisition deals have concentrated shares of the market increasingly in the hands of a few leading players, and have resulted in a clearer split between ownership of interests in the 'medicinal' and 'nutritional' segments of the industry. Over the same period, the expiry of patents on major molecules and new approaches to marketing animal health products have seen OTC sales channels increase in importance and generic manufacturers begin to play a more prominent role.
To reflect the changing nature of the industry, and to provide readers with a broader perspective, this edition of the report has been restructured. Pure animal nutrition businesses have been excluded, sharpening the focus of the study and enabling discussion of more companies that play a significant role in the core animal health market - a definition that spans veterinary pharmaceuticals, biologicals and medicinal feed additives.

Defined along those lines, the global market for animal health products was worth almost US$18.6 billion in 2006. The introductory section of this study discusses the size, structure and recent development of the global market, and examines factors affecting market growth rates. It also includes an analysis of recent merger and acquisition activity in the sector, presents tabulated company sales rankings for 2006 and ranking forecasts for 2007, and assesses the comparative profitability of leading animal health businesses.
More than two-thirds of global market value was generated by 13 major animal health businesses in 2006. Schering-Plough's pending acquisition of Intervet means that by the end of 2007, almost 70% of the market will be concentrated in the hands of 12 companies. SP's expanded animal health business will vie with Pfizer and Merial for outright leadership of the sector, with each of these three giants generating annual sales of more than US$2 billion. The combined market share held by the three leading players will be in excess of one-third.
The first group of profiles contained in the report includes all 12 of these 'animal health majors' - companies that are involved in the development, manufacture and sale of animal health products, and that operate in most of the world's leading national markets. Each profile describes the background and ownership of the relevant business and outlines its contribution to respective corporate sales. Recent performance is outlined through the presentation of five-year tabulated sales data (plus information on earnings where available) and descriptive text. The geography of the business is also analysed, while product portfolios are discussed in detail. An overview of research and development activity is presented, while each profile also includes an analysis of individual business strategies and commercial prospects for individual companies
The second group of profiles includes 14 businesses that, while not classed as 'animal health majors', play a significant role in the sector. This miscellaneous grouping includes 'second tier' companies such as Janssen and Orion, which boast track records in the discovery and development of proprietary animal health products, and Monsanto, which generates substantial revenues from a single product (its Posilac bovine somatotropin formulation). Leading representatives from the generic and OTC segments of the industry have also been included, along with high-profile players in Asia, some of which act as distributors in key markets that are difficult for multinationals to penetrate directly.

Financial information has been included in individual company profiles where available, but a ranking of the various businesses into a 'second-tier sales league' has not been attempted. This is partly because of the difficulties involved in stripping out core animal health product sales from revenues generated in peripheral areas (laboratory equipment and disposables, pet food, etc.). 'Double-counting' is also an issue, with Japanese companies in particular generating a substantial proportion of their reported revenues from the sale of multinational brands under licensing agreements with animal health majors. Contract manufacturing muddies the waters further, with some companies reporting revenues generated by toll-based production of products that are subsequently sold by third parties under their own labels, and that, similarly, are included in financial results posted by those companies.
Profiles in this section of the report include information on the background of individual businesses, plus an analysis of sales and recent revenue development. The geographical spread of each business is also discussed, product portfolios are analysed, and company strategies and prospects are assessed
Information sources used to compile this study include the Informa newsletter, Animal Pharm World Animal Health and Nutrition News; a range of other trade press sources; company web sites, annual reports, presentations and other corporate information; personal contacts within the industry; and direct contact with individual companies.

Contents

  • CHAPTER 1 INTRODUCTION
    • 1.1 The world market for animal health products
      • 1.1.1 Market shares by region
      • 1.1.2 Market shares by product category
      • 1.1.3 Market shares by species
    • 1.2 The animal health products industry
      • 1.2.1 Leading companies in the animal health sector
        • 1.2.1.1 Industry sales rankings in 2006
        • 1.2.1.2 Industry sales rankings in 2007
      • 1.2.2 Industry profit levels
    • 1.3 Currencies and exchange rates used in this report
  • SECTION A ANIMAL HEALTH MAJORS
  • CHAPTER 2 ALPHARMA
    • 2.1 Company background
    • 2.2 Animal health sales and operating profit
      • 2.2.1 2005 performance
      • 2.2.2 2006 performance
      • 2.2.3 Interim 2007 performance
    • 2.3 Geography of the business
      • 2.3.1 US
      • 2.3.2 International markets
    • 2.4 Product portfolio
      • 2.4.1 Antibiotics
      • 2.4.2 Anticoccidials
      • 2.4.3 Antibacterials
      • 2.4.4 Other products
    • 2.5 R&D
    • 2.6 Strategy
    • 2.7 Prospects
  • CHAPTER 3 BAYER
    • 3.1 Company background
    • 3.2 Animal health sales and earnings
      • 3.2.1 2005 performance
      • 3.2.2 2006 performance
      • 3.2.3 Interim 2007 performance
    • 3.3 Geography of the business
      • 3.3.1 North America
      • 3.3.2 Europe
      • 3.3.3 Asia/Pacific
      • 3.3.4 Latin America
    • 3.4 Product portfolio
      • 3.4.1 Antiparasitics
      • 3.4.2 Antimicrobials
      • 3.4.3 Other products
    • 3.5 R&D
    • 3.6 Strategy
    • 3.7 Prospects
  • CHAPTER 4 BOEHRINGER INGELHEIM
    • 4.1 Company background
    • 4.2 Animal health sales
      • 4.2.1 2005 performance
      • 4.2.2 2006 performance
      • 4.2.3 Interim 2007 performance
    • 4.3 Geography of the business
      • 4.3.1 Europe
      • 4.3.2 North America
      • 4.3.3 Other markets
    • 4.4 Product portfolio
      • 4.4.1 Pharmaceuticals
      • 4.4.2 Biologicals
      • 4.4.3 Other products
    • 4.5 R&D
    • 4.6 Strategy
    • 4.7 Prospects
  • CHAPTER 5 CEVA
    • 5.1 Company background
    • 5.2 Animal health sales and earnings
      • 5.2.1 2005 performance
      • 5.2.2 2006 performance
      • 5.2.3 Interim 2007 performance
    • 5.3 Geography of the business
      • 5.3.1 Europe
      • 5.3.2 North America
      • 5.3.3 International markets
    • 5.4 Product portfolio
      • 5.4.1 Companion animal products
      • 5.4.2 Reproductive controls
      • 5.4.3 Anti-infectives
      • 5.4.4 Vaccines
      • 5.4.5 Others
    • 5.5 R&D
    • 5.6 Strategy
    • 5.7 Prospects
  • CHAPTER 6 ELANCO
    • 6.1 Company background
    • 6.2 Animal health sales and operating income
      • 6.2.1 2005 performance
      • 6.2.2 2006 performance
      • 6.2.3 Interim 2007 performance
    • 6.3 Geography of the business
      • 6.3.1 US
      • 6.3.2 International markets
    • 6.4 Product portfolio
      • 6.4.1 Tylosin
      • 6.4.2 Tilmicosin
      • 6.4.3 Monensin
      • 6.4.4 Avilamycin
      • 6.4.5 Ractopamine
      • 6.4.6 Other products
    • 6.5 R&D
    • 6.6 Strategy
    • 6.7 Prospects
  • CHAPTER 7 FORT DODGE
    • 7.1 Company background
    • 7.2 Animal health sales and operating profit
      • 7.2.1 2005 performance
      • 7.2.2 2006 performance
      • 7.2.3 Interim 2007 performance
    • 7.3 Geography of the business
      • 7.3.1 US
      • 7.3.2 International markets
    • 7.4 Product portfolio
      • 7.4.1 Biologicals
      • 7.4.2 Antiparasitics
      • 7.4.3 Other pharmaceuticals
    • 7.5 R&D
    • 7.6 Strategy
    • 7.7 Prospects
  • CHAPTER 8 MERIAL
    • 8.1 Company background
    • 8.2 Animal health sales and operating income
      • 8.2.1 2005 performance
      • 8.2.2 2006 performance
      • 8.2.3 Interim 2007 performance
    • 8.3 Geography of the business
      • 8.3.1 US
      • 8.3.2 Europe
      • 8.3.3 International
    • 8.4 Product portfolio
      • 8.4.1 Avermectins
      • 8.4.2 Fipronil
      • 8.4.3 Biologicals
      • 8.4.4 Other products
    • 8.5 R&D
    • 8.6 Strategy
    • 8.7 Prospects
  • CHAPTER 9 NOVARTIS
    • 9.1 Company background
    • 9.2 Animal health sales and operating profit
      • 9.2.1 2005 performance
      • 9.2.2 2006 performance
      • 9.2.3 Interim 2007 performance
    • 9.3 Geography of the business
      • 9.3.1 North America
      • 9.3.2 Europe
      • 9.3.3 Other markets
    • 9.4 Product portfolio
      • 9.4.1 Antiparasitics
      • 9.4.2 Anti-infect
    • 15.6 Prospects
  • CHAPTER 16 DAINIPPON SUMITOMO PHARMA
    • 16.1 Company background
    • 16.2 Animal health sales
    • 16.3 Geography of the business
    • 16.4 Product portfolio
    • 16.5 Strategy
    • 16.6 Prospects
  • CHAPTER 17 HESKA
    • 17.1 Company background
    • 17.2 Animal health sales and operating profit
    • 17.3 Geography of the business
    • 17.4 Product portfolio
    • 17.5 Strategy
    • 17.6 Prospects
  • CHAPTER 18 IDEXX
    • 18.1 Company background
    • 18.2 Animal health sales
    • 18.3 Geography of the business
    • 18.4 Product portfolio
    • 18.5 Strategy
    • 18.6 Prospects
  • CHAPTER 19 JANSSEN
    • 19.1 Company background
    • 19.2 Animal health sales
    • 19.3 Geography of the business
    • 19.4 Product portfolio
    • 19.5 Strategy
    • 19.6 Prospects
  • CHAPTER 20 KYORITSU SEIYAKU
    • 20.1 Company background
    • 20.2 Geography of the business
    • 20.3 Product portfolio
    • 20.4 Strategy
    • 20.5 Prospects
  • CHAPTER 21 MEIJI SEIKA
    • 21.1 Company background
    • 21.2 Animal health sales
    • 21.3 Geography of the business
    • 21.4 Product portfolio
    • 21.5 Strategy
    • 21.6 Prospects
  • CHAPTER 22 MONSANTO
    • 22.1 Company background
    • 22.2 Animal health business
    • 22.3 Geography of the business
    • 22.4 Product portfolio
    • 22.5 Strategy
    • 22.6 Prospects
  • CHAPTER 23 NIPPON ZENYAKU
    • 23.1 Animal health sales
    • 23.2 Geography of the business
    • 23.3 Product portfolio
    • 23.4 Strategy
    • 23.5 Prospects
  • CHAPTER 24 NORBROOK
    • 24.1 Company background
    • 24.2 Animal health sales
    • 24.3 Geography of the business
    • 24.4 Product portfolio
    • 24.5 Strategy
    • 24.6 Prospects
  • CHAPTER 25 ORION
    • 25.1 Company background
    • 25.2 Animal health business
    • 25.3 Geography of the business
    • 25.4 Product portfolio
    • 25.5 Strategy
    • 25.6 Prospects
  • CHAPTER 26 PHIBRO
    • 26.1 Company background
    • 26.2 Animal health business
    • 26.3 Geography of the business
    • 26.4 Product portfolio
    • 26.5 Strategy
    • 26.6 Prospects
  • CHAPTER 27 TEVA
    • 27.1 Company background
    • 27.2 Animal health sales
    • 27.3 Geography of the business
    • 27.4 Product portfolio
    • 27.5 Strategy
    • 27.6 Prospects
  • LIST OF TABLES
    • Table 1.1: Geography of the world market, 2006
    • Table 1.2: World market structure by product category, 2006
    • Table 1.3: World market structure by species, 2006
    • Table 1.4: Animal health industry sales rankings, 1996 and 2006
    • Table 1.5: Animal health company sales rankings, 2006
    • Table 1.6: Animal health company sales ranking forecasts, 2007
    • Table 1.7: Animal health company profit rankings, 2006
    • Table 1.8: Animal health company profit margins, 2002-2006
    • Table 2.1: Alpharma's revenues by division, 2006
    • Table 2.2: Alpharma animal health sales, 2002-2006
    • Table 2.3: Alpharma animal health income and margins, 2002-2006
    • Table 2.4: Alpharma first half sales, 2006 and 2007
    • Table 2.5: Alpharma animal health revenues by region, 2006
    • Table 2.6: Alpharma's major product sales, 2006
    • Table 3.1: Bayer sales by operating segment, 2006
    • Table 3.2: Bayer animal health sales, 2002-2006
    • Table 3.3: Bayer animal health earnings and margins
    • Table 3.4: Bayer's first half sales, 2006-2007
    • Table 3.5: Bayer animal health sales by region, 2006
    • Table 4.1: Boehringer Ingelheim sales by business area, 2006
    • Table 4.2: BIV sales, 2002-2006
    • Table 4.3: BIV sales by region, 2006
    • Table 4.4: Sales of major BIV brands, 2006
    • Table 5.1: Ceva animal health sales, 2002-2006
    • Table 5.2: Ceva earnings and operating margins, 2002-2006
    • Table 5.3: Acquisitions completed by Ceva since 2000
    • Table 6.1: Elanco's animal health sales, 2002-2006
    • Table 6.2: Elanco's operating income and margin, 2002-2006
    • Table 6.3: Elanco's interim 2007 sales performance
    • Table 6.4: Elanco's US/international sales split, 2002-2006
    • Table 7.1: Wyeth sales by operating segment, 2006
    • Table 7.2: Fort Dodge animal health sales, 2002-2006
    • Table 7.3: Fort Dodge operating income and margins, 2002-2006
    • Table 7.4: Fort Dodge first half sales, 2006-2007
    • Table 7.5: Fort Dodge US/international sales split, 2002-2006
    • Table 7.6: Fort Dodge sales by species, 2006
    • Table 8.1: Merial animal health sales, 2002-2006
    • Table 8.2: Merial first half animal health sales, 2006 and 2007
    • Table 8.3: Merial sales by product category, 2006
    • Table 8.4: Merial's avermectin revenues, 2002-2006
    • Table 8.5: Leading formulations in the Merial ivermectin range
    • Table 8.6: Fipronil sales, 2002-2006
    • Table 9.1: Novartis sales by operating segment, 2006
    • Table 9.2: Novartis animal health sales, 2002-2006
    • Table 9.3: Novartis animal health sales by region, 2006
    • Table 9.4: Novartis animal health sales by product segment, 2006
    • Table 10.1: Pfizer sales by operating segment, 2006
    • Table 10.2: Pfizer animal health sales, 2002-2006
    • Table 10.3: Pfizer animal health earnings and margins, 2002-2006
    • Table 10.4: Pfizer first half animal health sales, 2006 and 2007
    • Table 10.5: Pfizer's US/international sales split, 2005 and 2006
    • Table 10.6: Pfizer animal health sales by species segment, 2005 and 2006
    • Table 10.7: Recent additions tthe Pfizer anti-infectives range
    • Table 11.1: Schering-Plough sales by business sector, 2006
    • Table 11.2: SPAH sales, 2002-2006
    • Table 11.3: SPAH earnings and divisional margins, 2002-2006
    • Table 11.4: SPAH first half sales, 2006 and 2007
    • Table 11.5: SPAH's US/international sales split, 2005 and 2006
    • Table 11.6: Geography of the expanded SPAH business
    • Table 12.1: Vtoquinol sales, 2002-2006
    • Table 12.2: Vtoquinol's first-half sales, 2006 and 2007
    • Table 12.3: Vtoquinol sales by region, 2006
    • Table 12.4: Vtoquinol's key acquisitions
    • Table 12.5: Vtoquinol sales by product category, 2006
    • Table 13.1: Virbac animal health sales, 2002-2006
    • Table 13.2: Virbac first half sales, 2006 and 2007
    • Table 13.3: Virbac sales by region, 2006
    • Table 13.4: Virbac sales by product segment, 2006
    • Table 14.1: CG&P sales by operating segment, 2006
    • Table 15.1: CAHIC financial results, 2004-2006
    • Table 15.2: CAHIC sales by product segment, 2006
    • Table 16.1: DSP sales by operating segment, fiscal 2007
    • Table 16.2: DSP Animal Science sales, 2003-2007
    • Table 16.3: DSP Animal Science sales by product segment
    • Table 17.1: Heska earnings and income, 2002-2006
    • Table 17.2: Heska revenues, 2002-2006
    • Table 17.3: Heska revenues by geographic area
    • Table 17.4: Heska revenues by product category
    • Table 18.1: Idexx sales by operating segment, 2006
    • Table 18.2: Idexx sales by region, 2006
    • Table 18.3: Idexx companion animal rapid diagnostic assay sales
    • Table 18.4: Idexx veterinary pharmaceutical sales
    • Table 20.1: Kyoritsu Seiyaku animal health sales and growth rates
    • Table 22.1: Monsantsales by operating segment, 2006
    • Table 23.1: NZK sales by product sector
    • Table 24.1: Norbrook sales and earnings, 2002-2006
    • Table 25.1: Orion sales by business sector, 2006
    • Table 25.2: Orion's veterinary sedative sales, 2002-2006
    • Table 27.1: Teva sales by operating segment, 2006